PATHOLOGY OF INBORN SKELETAL DISEASES
先天性骨骼疾病的病理学
基本信息
- 批准号:2856135
- 负责人:
- 金额:$ 20.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1986
- 资助国家:美国
- 起止时间:1986-07-01 至 2000-07-31
- 项目状态:已结题
- 来源:
- 关键词:Ehlers Danlos syndrome achondroplasia biopsy chondrodystrophy collagen disorder congenital skeletal disorder crosslink extracellular matrix family genetics gene mutation genetic polymorphism high performance liquid chromatography histopathology human subject human tissue hydroxyaminoacid hydroxyproline lysine molecular pathology mucopolysaccharidosis type IV osteoarthritis osteogenesis imperfecta posttranslational modifications protein sequence protein structure function tissue /cell culture
项目摘要
This project is defining at the protein level the molecular basis of
heritable disorders of collagen metabolism that cause skeletal disease.
The goal is to understand the consequences of mutations in collagen genes
in terms of expressed protein structure and altered macromolecular
interactions in the extracellular matrix. The specific aims include
understanding the molecular effects of type II collagen defects that
include amino acid substitutions caused by single base changes and full
and partial exon deletions caused by splice site mutations. Rules in the
relationship between underlying gene defect, expressed protein
abnormality, tissue pathology and clinical phenotype will be explored.
Changes in post-translational chemistry of collagen molecules bearing
mutant chains, that is in proline hydroxylation, lysine hydroxylation,
hydroxylysine glycosylation and intermolecular cross-linking will be
examined, pursuing an hypothesis that the quality of such secondary
changes are important determinants of the clinical phenotype and disease
severity. The approach is to apply methods in protein analysis (peptide
mapping and gas-phase sequencing adapted for the special features of
collagen chemistry) to human tissue specimens. Tissues from defined cases
of chondrodysplasia including achondrogenesis/hypochondrogenesis,
spondyloepiphyseal dysplasia (SED), spondyloepimetaphyseal dysplasia
(SEMD), Kniest dysplasia and familial osteoarthrosis/mild SED will be
studied. Defects at the protein level in collagen types IX, X and XI will
also be sought in the extracellular matrix using a similar approach. The
nature of the collagen cross-linking defect in Ehlers-Danlos syndrome VI
will be pursued. Common features of the pathology of bone matrix collagen
in osteogenesis imperfecta will also be explored at the protein level. The
significance of the work is the major impact collectively of overt
heritable skeletal diseases, and also of related mild mutations and
genetic polymorphisms that are strongly suspected to predispose to the
common disorders of the aging skeleton, osteoporosis and osteoarthritis.
With the increasing burden in life quality and health care delivery of
degenerative disorders of the skeleton, understanding the molecular basis
and prevalence of such genetic factors is essential if effective
diagnostic, preventive and therapeutic strategies are to be pursued.
该项目在蛋白质水平上定义了
导致骨骼疾病的胶原代谢遗传性紊乱。
目的是了解胶原基因突变的后果
在表达的蛋白质结构和改变的大分子
细胞外基质中的相互作用。具体目标包括
了解II型胶原蛋白缺陷的分子效应,
包括由单个碱基变化引起氨基酸取代,
和由剪接位点突变引起的部分外显子缺失。规则
潜在基因缺陷、表达蛋白
将探索异常、组织病理学和临床表型。
胶原蛋白分子翻译后化学的变化
突变链,即脯氨酸羟基化,赖氨酸羟基化,
羟基赖氨酸糖基化和分子间交联将
研究,追求一个假设,这种次要的质量
变化是临床表型和疾病的重要决定因素
严重性。该方法是将方法应用于蛋白质分析(肽
映射和气相测序适合的特殊功能,
胶原化学)应用于人体组织样本。定义病例的组织
软骨发育不良,包括软骨发育不全/软骨发育不良,
脊椎骨骺发育不良(SED),脊椎骨骺发育不良
(SEMD)、最严重的发育不良和家族性骨关节病/轻度SED将被
研究了IX、X和XI型胶原蛋白中蛋白质水平的缺陷将
也可以使用类似的方法在细胞外基质中寻找。的
Ehlers-Danlos综合征VI中胶原交联缺陷的性质
将被追究。骨基质胶原病理的共同特征
还将在蛋白质水平上探索成骨不全症的发病机制。的
这项工作的意义是公开的集体的重大影响,
遗传性骨骼疾病,以及相关的轻度突变,
基因多态性,强烈怀疑易患
常见的骨骼老化、骨质疏松症和骨关节炎。
随着生活质量和医疗保健服务负担的增加,
骨骼的退化性疾病,了解分子基础
如果有效,这些遗传因素的流行是必不可少的
将采取诊断、预防和治疗战略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David R Eyre其他文献
David R Eyre的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David R Eyre', 18)}}的其他基金
CONFERENCE ON BIOENGINEERING AND ORTHOPAEDIC SCIENCES
生物工程和骨科科学会议
- 批准号:
2080965 - 财政年份:1992
- 资助金额:
$ 20.18万 - 项目类别:
COLLAGENS OF CARTILAGE AND THE INTERVERTEBRAL DISC
软骨和椎间盘的胶原蛋白
- 批准号:
2909785 - 财政年份:1986
- 资助金额:
$ 20.18万 - 项目类别:
相似海外基金
Exploring the genetic background of normal facial variation to dissect disease expressivity, using achondroplasia as a model.
以软骨发育不全为模型,探索正常面部变异的遗传背景,以剖析疾病的表现力。
- 批准号:
486257 - 财政年份:2022
- 资助金额:
$ 20.18万 - 项目类别:
Studentship Programs
Development of therapeutic drugs fro achondroplasia-Examination of FGFR3 inhibitory effects of meclizine hydrochloride
软骨发育不全治疗药物的研制——盐酸美其嗪对FGFR3抑制作用的考察
- 批准号:
21H03063 - 财政年份:2021
- 资助金额:
$ 20.18万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidation of the relationship between obesity and type 2 diabetes in achondroplasia
阐明肥胖与软骨发育不全中 2 型糖尿病之间的关系
- 批准号:
19K23996 - 财政年份:2019
- 资助金额:
$ 20.18万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Examination of obesity and insulin resistance for patient cohort and disease-specific iPS cells with achondroplasia
检查患有软骨发育不全的患者群体和疾病特异性 iPS 细胞的肥胖和胰岛素抵抗
- 批准号:
18K07877 - 财政年份:2018
- 资助金额:
$ 20.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Early intervention for children with achondroplasia: self-management and self-efficacy
软骨发育不全儿童的早期干预:自我管理和自我效能
- 批准号:
26861923 - 财政年份:2014
- 资助金额:
$ 20.18万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
8675729 - 财政年份:2010
- 资助金额:
$ 20.18万 - 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
8129527 - 财政年份:2010
- 资助金额:
$ 20.18万 - 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
8277448 - 财政年份:2010
- 资助金额:
$ 20.18万 - 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
8476987 - 财政年份:2010
- 资助金额:
$ 20.18万 - 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
- 批准号:
7987228 - 财政年份:2010
- 资助金额:
$ 20.18万 - 项目类别:














{{item.name}}会员




